tbuckley/cabot-search huggingface dataset:
Identification of predictive markers of response to 5-Fluorouracil and oxaliplatin in metastatic colorectal cancer
Authors: Wendy L. Allen, John Boyer, Vicky Coyle, Andrea McCulla, Estelle G. McLean, Daniel B. Longley, Patrick G. Johnston
Journal: Cancer Research (2006)

3390  Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the Western world. The most active drug against this malignancy is 5 Fluorouracil (5FU), which produces response rates of only 20 to 25% in advanced CRC. Efforts to improve efficacy have led to combination of 5FU with newer agents such as Irinotecan and Oxaliplatin, which have significantly improved response rates to 40 to 50%. Despite these improvements, less than half of patients who undergo chemotherapy will receive any benefit from treatment. A major factor limiting the effectiveness of chemotherapy against CRC is inherent or acquired drug resistance. We have previously generated a panel of HCT116 CRC cell lines resistant to 5FU and Oxaliplatin by repeated exposure to stepwise increasing concentrations of drug over a period of months. We have used these model cell lines in conjunction with DNA microarray technology to identify novel determinants of response to 5FU and Oxaliplatin. Using data analysis software (Genespring and SAM), we have identified panels of genes whose expression is constitutively altered in drug resistant cells relative to sensitive parental cells and induced following acute exposure of parental cells to drug. In total, 119 genes and 37 genes were identified that correlate with 5FU and Oxaliplatin sensitivity respectively. These data suggest that cancer cells may recruit and activate the expression of a distinct set of genes in transient induction or when selected for resistance to chemotherapy. We propose that this set of genes may represent a distinct molecular signature indicative of drug resistance. Using real time RT PCR, we have successfully validated a representative subset of these genes and calculated r squared values to examine the robustness of our microarray data set. Using Genespring, we have carried out advanced data mining of both the 5-FU and oxaliplatin datasets in a time- and gene-dependent manner. We have used several different clustering methods to identify patterns of gene expression within our datasets. Gene ontology analysis has identified groups of genes involved in response to either oxaliplatin or 5-FU. Furthermore, this analysis has demonstrated that the majority of differential gene expression occurs at 6h in the oxaliplatin dataset and that this is maintained to 24h, whereas the majority of genes are differentially regulated at 24h in the 5-FU dataset. Pathway analysis has further identified several pathways involved in either 5-FU or oxaliplatin response. We are currently testing the predictive accuracy of these genes in a panel of pretreatment metastatic CRC biopsies, using a two-step supervised classification approach. Ultimately, the data from these analyses will be used to design a prospective trial, in which treatment for CRC is administered on the basis of the molecular profile of both tumour and patient.
Trudi Pervovo Syezda Onkologov Ukrainskoi Sovetskoi Sotsialisticheskoi Respubliki. [The Works of the First Convention of Onkologists of the Ukrainian Soviet Socialist Republic.] Edited by A. A. Bogomoletz, R. E. Kavetsky, and A. V. Melnikov. “Medgiz,” Narkomzdrav, S.S.S.R., Moscow-Leningrad. 1940. 547 pages. In Russian. Price, bound, 45 rubles
Authors: Michael B. Shimkin
Journal: Cancer Research (1944)
Mentally stimulating activities reduce risk of mild cognitive impairment, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Regularly engaging in mentally stimulating activities such as playing games, using a computer, or doing crafts is associated with reduced risk of developing mild cognitive impairment in healthy older people, a prospective cohort study has found.1

Researchers prospectively followed up 1929 cognitively normal people aged 70 or older (median 77 years, interquartile range 74-82) for a median of 4.0 years. They were recruited from the ongoing population based Mayo Clinic Study of Aging, which is investigating ageing in older people living in Olmsted County, Minnesota, USA.

Participants …
SURG-05MOLECULAR CORRELATES OF TUMOR SIZE AND MRI CONTRAST ENHANCEMENT IN A COHORT OF LOWER-GRADE GLIOMA PATIENTS
Authors: Shilpa Tummala, Daniel Cahill
Journal: Neuro-Oncology (2015)

Lower-grade gliomas (LGGs) are classified by recurrent mutations in the IDH1/2 and TP53/ATRX genes, the TERT promoter, and chromosome 1p/19q loss. These alterations cluster tumors into three  groups with distinct prognoses: the molecular astrocytic (group A) defined by co-presence of IDH1/2 and TP53-and/or-ATRX mutation, molecular oligodendroglial (group O) defined by presence of IDH1/2 mutation and absence of TP53/ATRX mutations, and molecular glioblastoma-like(group G) defined by absence of IDH1/2 mutation. Here, we examined the traditional clinical heuristic of tumor size, assessed by T2/FLAIR and T1 post-gadolinium MRI contrast enhancement (both measured by the product of two orthogonal dimensions on the axial MRI image with the greatest tumor area), within the three  groups from cases in the TGCA LGG cohort with available image data in TCIA (n = 172). Upon examination of preoperative MRIs, median tumor measurement by T2/FLAIR was 31.96 cm2 in group A, 19.14 cm2 in group O, and 17.45 cm2 in group G. Notwithstanding this larger size, only 19/85 group A tumors had enhancing area > 10% of the overall tumor size, while 11/47 group O and 24/40 group G gliomas showed similar extent-of-enhancement. Thus, group G gliomas were more frequently enhancing (p = 0.0001 and p = 0.0009 for the comparisons between group A and O respectively, Fisher's exact test). The prognostic impact of contrast enhancement may therefore reflect, in part, this differing distribution between  groups. Indeed, WHO grade was also partially linked to enhancement, with 10 of 83 grade II tumors displaying enhancing areas >10% of the overall tumor size, while 44 of 89 grade III tumors were similarly enhancing. Given the inability to identify  categories of low-risk tumors from clinical and radiographic factors alone, we conclude that surgical resection or biopsy is indicated in all suspected LGGs, to facilitate  group assignment and guide further therapy.
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697)
Authors: Sanjiv S. Agarwala, Sandra J. Lee, Waiki Yip, Uma N. Rao, Ahmad A. Tarhini, Gary I. Cohen, Douglas S. Reintgen, Terry L. Evans, Joanna M. Brell, Mark R. Albertini, Michael B. Atkins, Shaker R. Dakhil, Robert M. Conry, Jeffrey A. Sosman, Lawrence E. Flaherty, Vernon K. Sondak, William E. Carson, Michael G. Smylie, Alberto S. Pappo, Richard F. Kefford, John M. Kirkwood
Journal: Journal of Clinical Oncology (2017)

Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) in patients with surgically resected intermediate-risk melanoma. Patients and Methods In this intergroup international trial, eligible patients had surgically resected cutaneous melanoma in the following categories: (1) T2bN0, (2) T3a-bN0, (3) T4a-bN0, and (4) T1-4N1a-2a (microscopic). Patients were randomly assigned to receive IFN α-2b at 20 MU/m2/d IV for 5 days (Monday to Friday) every week for 4 weeks (IFN) or OBS. Stratification factors were pathologic lymph node status, lymph node staging procedure, Breslow depth, ulceration of the primary lesion, and disease stage. The primary end point was relapse-free survival. Secondary end points included overall survival, toxicity, and quality of life. Results A total of 1,150 patients were randomly assigned. At a median follow-up of 7 years, the 5-year relapse-free survival rate was 0.70 (95% CI, 0.66 to 0.74) for OBS and 0.70, (95% CI, 0.66 to 0.74) for IFN ( P = .964). The 5-year overall survival rate was 0.83 (95% CI, 0.79 to 0.86) for OBS and 0.83 (95% CI, 0.80 to 0.86) for IFN ( P = .558). Treatment-related grade 3 and higher toxicity was 4.6% versus 57.9% for OBS and IFN, respectively ( P < .001). Quality of life was worse for the treated group. Conclusion Four weeks of IV induction as part of the Eastern Cooperative Oncology Group high-dose IFN regimen is not better than OBS alone for patients with intermediate-risk melanoma as defined in this trial.
TMIC-02CELL AUTONOMOUS AND CELL NON-AUTONOMOUS ROLES OF p75 NEUROTROPHIN RECEPTOR (p75<sup>NTR</sup>) IN GLIOMA INVASION
Authors: Mana Alshehri, Bo Young Ahn, Xiuling Wang, Tanveer Shiekh, Jennifer Chan, Donna Senger, Stephen Robbins
Journal: Neuro-Oncology (2015)
Highly Multiplexed Targeted Sequencing of Recurrent Fusion Genes in Acute Leukemia
Authors: Philippe Ruminy, Nimrod Buchbinder, Thomas Larson, Vinciane Marchand, Bérangère Joly, Sylvain Mareschal, Mathieu Viennot, Marie Cornic, Elodie Bohers, Philippe Bertrand, Dominique Penther, Pascaline Etancelin, Vincent Camus, Sydney Dubois, Stéphane Lepretre, Emilie Lemasle, Gérard Buchonnet, Florian Clatot, Pascale Schneider, Jean-Michel Picquenot, jean-Pierre Vannier, Christian Bastard, Herve Tilly, Fabrice Jardin
Journal: Blood (2014)
Identification of a STAT3-miRNA Axis in T-LGL Leukemia
Authors: Renato Zambello, Barbara Mariotti, Antonella Teramo, Marzia Rossato, Gregorio Barilà, Giulia Calabretto, Chiara Ercolin, Tamara Berno, Livio Trentin, Monica Facco, Gianpietro Semenzato, Flavia Bazzoni
Journal: Blood (2015)
Upper Airway Collapsibility Assessed By Negative Expiratory Pressure While Awake Is Associated With Tongue Dimensions And Hyoid Position
Authors: R. P. Hirata, F. Kayamori, F. Schorr, P. R. Genta, H. T. Moriya, S. Romano, G. Insalaco, L. F. Oliveira, G. Lorenzi-Filho
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
Becoming an expert: Ontogeny of expertise as an example of neural reuse
Authors: Alessandro Guida, Guillermo Campitelli, Fernand Gobet
Journal: Behavioral and Brain Sciences (2016)

In this commentary, we discuss an important pattern of results in the literature on the neural basis of expertise: (a) decrease of cerebral activation at the beginning of acquisition of expertise and (b) functional cerebral reorganization as a consequence of years of practice. We show how these two results can be integrated with the neural reuse framework.
ANGI-01NANONIZATION OF HET0016 IMPROVED THE CONTROL OF GMB IN RAT MODEL
Authors: Nipuni Gomez, Adarsh Shankar, Meenu Jain, Austin Guo, Roxan Ara, Bhagelu Achyut, Hassan Bagher-Ebadian, Alfonso Scicli, Meser Ali, Ali Arbab
Journal: Neuro-Oncology (2015)

N-hydroxy-N'-(4-butyl-2 methylphenyl) formamidine (HET0016) has been reported to be a highly selective inhibitor of 20-hydroxy arachidonic acid (20-HETE) synthesis that involves enzymes of the cytochrome P450, family 4, subfamily A (CYP4A) and CYP4F families. HET0016 was found to inhibit angiogenic responses to several growth factors as well as angiogenesis in the cornea induced by implanted human U251 glioma cells and angiogenesis in 9L gliosarcoma. Recently our group has published the effectiveness of HET0016 in controlling different malignant tumors in animal models. However, to achieve optimal blood level of the administered HET0016 to control tumor growth, HET0016 is administered intraperitoneally (IP) two times a day for 7 days a week. HET0016 is highly insoluble in water and needs an organic solvent such as DMSO or ethanol for making formulation for IP administration. We have nanonized HET0016 for IV formulation using FDA approved nanoparticle and administered in rats bearing orthotopic human glioma. Animals were treated at different stages of tumor growth and the effect of the IV formulation was investigated by magnetic resonance imaging (MRI). All animals were euthanized on day 22 of tumor implantation for molecular and immunohistochemical analysis. All the findings were compared with that of corresponding animals treated with vehicle and HET0016 (intraperitoneal administration).IV administration of nanonized HET0016 significantly decreased the growth of the tumor at all treatment schedules. Effect was pronounced when treatments started in developed tumors (8 or 15 days old tumor). IP administration did not significantly decrease the tumor growth. Vascular parameters were also significantly altered when HET0016 was administered IV in 8 days old tumor. Whereas IP administered tumor did not show any significant changes compared to that of corresponding control. Released of different growth factors and tumor cell migration were significantly decreased in IV administered animals.
Frequency of the JAK2 Mutation and Its Usefulness as a Marker for Treatment Response and Disease Progression in Korean Patients with Chronic Myeloproliferative Disorders.
Authors: Myung-Geun Shin, Hyeoung Joon Kim, Hye-Ran Kim, Sun-Young Lee, Il-Kwon Lee, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang
Journal: Blood (2006)
Beyond perceptual judgment: Categorization and emotion shape what we see
Authors: Steven B Most
Journal: Behavioral and Brain Sciences (2016)

By limiting their review largely to studies measuring perceptual judgment, Firestone & Scholl (F&S) overstate their case. Evidence from inattentional blindness and emotion-induced blindness suggests that categorization and emotion shape what we perceive in the first place, not just the qualities that we judge them to have. The role of attention in such cases is not easily dismissed as "peripheral."
Cord Blood Transplantation for Adult Acute Lymphoblastic Leukemia.
Authors: Tomomi Kawano, Tomoko Matsumura, Shinsuke Takagi, Daisuke Kato, Koichiro Yuji, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, Shuichi Taniguchi
Journal: Blood (2005)
BMET-01ADJUVANT SRS DOES NOT PREDICT DISTANT BRAIN FAILURE OR WORSENED OVERALL SURVIVAL POST-OPERATIVELY VERSUS WBRT
Authors: Jacob Witt, Christopher Abraham, Todd DeWees, Cliff Robinson
Journal: Neuro-Oncology (2015)

BACKGROUND: The optimal choice of adjuvant radiation treatment of brain metastasis (BM) following metastectomy is unclear. Following metastectomy, whole brain irradiation (WBI) has been shown to increase both local (LC) and distant (DC) CNS control, however, at the expense of worsening neurocognition. SRS offers excellent local control, yet at the cost of decreased DC. The purpose of this work was to compare LC, DC, and overall survival (OS) for WBI vs SRS. METHODS: Patients with BM treated with metastectomy followed by single fraction SRS or WBRT from 2001-2013 were identified from an IRB-approved registry. Patient, tumor, and treatment related variables were collected in retrospective fashion. Clinical follow up with MR imaging was obtained every 3 months and was reviewed from time of SRS or end of WBRT to death or last follow up. LC was graded in each treated lesion and was defined as stability or decrease in the size of the treated BM at any time post-SRS. RESULTS: 104 patients were identified; 72 in the SRS group and 32 in the WBRT group. On univariate analysis, sex was the only significant factor impacting LC (p = 0.017). Univariate analysis of DC demonstrated no significant variables. OS at 12 months was 62%. SRS (p = 0.029), age (p = 0.001), and number of metastases (p = 0.027) were significant on univariate analysis for OS. Age (p = 0.001) remained significant on multivariate analysis for OS, while SRS did not. CONCLUSIONS: SRS following metastectomy is not an independent predictor of distant brain failure or a detriment to OS. Given the known detriment to neurocognition, it is safe to omit WBRT post-metastectomy in lieu of SRS for the treatment of BM.
Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56+Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56+Dim NK Cells
Authors: Nancy S Day, Evan Shereck, Janet Ayello, Catherine McGuinn, Prakash Satwani, Juliana Atallah, Carmella van de Ven, Ronald J Wapner, Megan S. Lim, Mitchell S. Cairo
Journal: Blood (2010)
The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies.
Authors: V. Singh, J. Krishnamurthy, O. Frankfurt, Andrew M Evens, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta
Journal: Blood (2008)
Stromal Cell IL-8 Production Is Increased in MM and May Impact Both Tumor Cells and the Microenvironment.
Authors: Michael Kline, Kathleen Donovan, Linda Wellik, Christopher Lust, Wendy Jin, Laurie Moon-Tasson, Shaji Kumar, Thomas E. Witzig, S. Vincent Rajkumar, John A. Lust
Journal: Blood (2005)
Efficacy and Safety of Micafungin for the Prophylaxis of Invasive Fungal Disease During Neutropenia in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Hyeon Jin Park, Meerim Park, Mira Han, Byung Ho Nam, Kyung Nam Koh, Ho Joon Im, Jae Wook Lee, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Keon Hee Yoo, Hong Hoe Koo, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Young Tak Lim, Hoon Kook, Chuhl Joo Lyu, Jeong Ok Hah, Jun Eun Park, Jong Jin Seo
Journal: Blood (2012)
The short-term and long-term effects of bariatric/metabolic surgery on subcutaneous adipose tissue inflammation in humans
Authors: Derek K. Hagman, Ilona Larson, Jessica N. Kuzma, Gail Cromer, Karen Makar, Katya B. Rubinow, Karen E. Foster-Schubert, Brian van Yserloo, Peter S. Billing, Robert W. Landerholm, Matthew Crouthamel, David R. Flum, David E. Cummings, Mario Kratz
Journal: Metabolism (2017)
DDEL-10MICRONENVIRONMENTAL MODULATION IMPROVES NANOMEDICINE DELIVERY INTO BRAIN TUMORS
Authors: Betty Y.S. Kim, Yuanxin Chen, Joshua Knight, Christina Von Roemeling, Yaqing Qie, Xiujie Liu, Hengfeng Yuan, Wen Jiang, Han Tun, Robert Wharen
Journal: Neuro-Oncology (2015)

One of the key challenges in cancer nanotechnology is to efficiently deliver nanomedicine into solid tumors. Nanomedicine relies on a functional vascular network and minimal tissue resistance to achieve homogeneous transport and distribution in solid tumor via convection- and diffusion-based mechanisms. This is especially true for brain tumors, where the presence of specialized blood brain barrier further impedes transport of nanomedicine from the systemic circulation into the central nervous system. Unlike blood vessels within healthy tissues, tumor vessels are often morphologically pathologic and functionally impaired, due to an imbalance of pro- and anti-angiogenic growth factor production within the tumor microenvironment. Furthermore, within the tumor stroma, excessive and heterogeneous productions of collagen and other matrix proteins further restrict nanomedicine distribution. We characterized the perfusion and diffusion parameters of luminescent nanoparticles within syngeneic GL261 brain tumor models using multi-photon imaging, in vivo. We demonstrated that brain tumor vasculatures exhibit increased permeability and decreased perfusion capacity compared to normal vessels. As a result, transport of nanomedicine across the vessel wall into the tumor stroma is strongly dependent on particle size and surface polarity. Furthermore, intratumoral mapping of nanomedicine distributions revealed that once gaining entry into tumors, nanoparticles often experience perivascular clumping and are unable to reach tumor tissue beyond 20 µm from the nearest vessels. Finally, with therapeutic modulation of the tumor microenvironment using anti-VEGFR or anti-TGF-β1 antibody treatments to remodel the tumor vasculature and collagen matrix, respectively, we showed that tumors begin to exhibit improved tissue perfusion with improved delivery and distribution with nanomedicine into the tumor interstitium. These findings suggest that optimized delivery of nanomedicine for brain tumors may be possible through the modulation of both the tumor vasculature and extracellular matrix. The successful implementation of this combined therapeutic approach can have significant implications in developing more effective targeted nanomedicines for brain tumors.
Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.
Authors: Ralf Angermund, W. Knauf, M. Freund, M. Nowrousian, H. Einsele, H. Goldschmidt, W. Berdel, W. Poenisch, C. Straka, L. Kellermann, H. Pliskat
Journal: Blood (2006)
Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution
Authors: Paul Szabolcs, Rebecca Buckley, Robert Duane Davis, Judith Voynow, Jerelyn Moffet, Antony Jeyaraj, David W Zaas
Journal: Blood (2011)
Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.
Authors: Ronald P. Taylor, Paul V. Beum, P. Todd Stukenberg, Andrew W. Pawluczkowycz, Margaret A. Lindorfer, Frank J. Beurskens, Paul W. H. I. Parren, Jan G. J. van de Winkel
Journal: Blood (2008)
MRD-Detection by Multiparametric Flow Cytometry in Childhood Precursor B-Cell All:Predictive Impact of Early Blast Reduction Kinetics in Peripheral Blood (PB) on MRD-Level in Bone Marrow (BM) at Day 33 of the All-BFM2000 Potocol.
Authors: Richard Ratei, Mathilde Martin, Guiseppe Basso, Guiseppe Gaipa, Martin Schrappe, Michael Dworzak5, Wolf-Dieter Ludwig, Leonid Karawajew
Journal: Blood (2004)
Patterns of Relapse and Value of Follow up Procedures in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Achieve a Complete Remission (CR)
Authors: Yasuhiro Oki, Dai Chihara, Yoshitoyo Kagami, Shouji Ine, Harumi Kato, Hirofumi Taji, Kazuhito Yamamoto, Yasuo Morishima
Journal: Blood (2008)
MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.
Authors: Mridul Agrawal, Philipp Erben, Benjamin Hanfstein, Hannah Daikeler, Juliana Popa, Thomas Schenk, Armin Leitner, Richard C. Woodman, Andreas Hochhaus, Martin C Müller
Journal: Blood (2009)
Representation of affect in sensory cortex
Authors: Vladimir Miskovic, Karl Kuntzelman, Junichi Chikazoe, Adam K Anderson
Journal: Behavioral and Brain Sciences (2016)

Abstract Contemporary neuroscience suggests that perception is perhaps best understood as a dynamically iterative process that does not honor cleanly segregated “bottom-up” or “top-down” streams. We argue that there is substantial empirical support for the idea that affective influences infiltrate the earliest reaches of sensory processing and even that primitive internal affective dimensions (e.g., goodness-to-badness) are represented alongside physical dimensions of the external world.
Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma.
Authors: Daniel A. Heinrich, Christian Klein, Kristina Decheva, Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Tobias Weiglein, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2009)
In Vitro Preclinical Study Results for a Phase I Adoptive Immunotherapy Trial Using Cetuximab in Association with Allogeneic NK Cell Infusion in KRAS Oncogene Mutated Metastatic Colorectal Cancer Patients.
Authors: Elisabetta Todisco, Francesca Re, Donatella Genovese, Ilaria Turin, Lorenza Rimassa, Adalberto Ibatici, Luca Castagna, Armando Santoro, Daniela Montagna
Journal: Blood (2009)
Antileukemic Efficacy of Anthocyanins In-Vitro and In-Vivo and In Combination with a DNA Vaccine Against Ph+ Acute Lymphoblastic Leukemia
Authors: Yvonne Rott, Michael Sagner, Hendrik Ungefroren, Manuel Schmidt, Burghardt Wittig, Egbert Herting, Joachim Köchling
Journal: Blood (2010)